Sequence-function relationship of influenza broadly neutralizing antibodies

流感广泛中和抗体的序列-功能关系

基本信息

项目摘要

PROJECT SUMMARY Influenza A virus continues to be a major global health concern due to antigenic drifts and shifts. Rapid antigenic drifts of circulating human influenza subtypes (H1N1 and H3N2), which are caused by point mutations, can drastically hamper vaccine effectiveness despite annual update of the seasonal influenza vaccine. On the other hand, antigenic shifts, which are caused by genetic reassortment between antigenically distinct strains, can result in devastating pandemic as exemplified by the 1918 Spanish flu. Human infections with different zoonotic subtypes, such as H5N1, H6N1, H7N9, H9N2, and H10N8 have also been reported. As a result, a universal influenza vaccine that can elicit broadly protective antibody responses to diverse influenza strains and subtypes is urgently needed. The discovery of broadly neutralizing antibodies (bnAbs) that target the conserved stem region of influenza hemagglutinin (HA) has raised the possibility of developing a universal influenza vaccine. A number of HA stem bnAbs are encoded by immunoglobulin heavy chain germline gene IGHV6-1. Since these IGHV6-1 HA stem bnAbs can be found in multiple individuals and can cross-react with both group 1 HAs (H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16) and group 2 HAs (H3, H4, H7, H10, H14, and H15), they represent the type of antibody response that needs to be induced by a universal influenza vaccine. This proposed study will use innovative high-throughput experiments to define sequence features in the heavy-chain complementarity-determining region 3, light chain, and somatic hypermutations, that enable an IGHV6-1 antibody to be a cross-group HA stem bnAbs. The underlying molecular mechanisms will be further characterized by structural biology approach. The results will help accurately estimate the germline frequency of IGHV6-1 HA stem bnAbs and understand their affinity maturation pathway, which in turn will benefit the design of a universal influenza vaccine. Furthermore, the experimental framework established in this study will be applicable to characterize any antibody of interest.
项目摘要 由于抗原漂移和转变,甲型流感病毒仍然是一个主要的全球健康问题。快速 流行的人流感亚型(H1N1和H3 N2)的抗原漂移,这是由点 尽管季节性流感每年都有更新, 疫苗另一方面,抗原性转变,这是由抗原性之间的遗传重配引起的, 不同的菌株,可以导致毁灭性的大流行,如1918年西班牙流感。人类感染 与不同的人畜共患病亚型,如H5 N1,H6 N1,H7N9,H9 N2和H10 N8也有报道。作为 因此,一种通用流感疫苗,可以引发对不同流感的广泛保护性抗体反应, 菌株和亚型。发现了靶向靶向的广泛中和抗体(bnAb), 流感病毒血凝素(HA)的保守干细胞区提高了开发通用 流感疫苗。许多HA茎bnAb由免疫球蛋白重链种系基因编码, IGHV6-1。由于这些IGHV 6 -1 HA干bnAb可以在多个个体中发现,并且可以与IGHV 6 - 1 HA干bnAb交叉反应, 第1组HA(H1,H2,H5,H6,H8,H9,H11,H12,H13和H16)和第2组HA(H3,H4,H7,H10,H14, 和H15),它们代表了需要由通用流感病毒诱导的抗体应答类型 疫苗这项拟议的研究将使用创新的高通量实验来定义序列特征, 重链互补决定区3、轻链和体细胞超突变, IGHV 6 -1抗体是交叉组HA茎bnAb。潜在的分子机制将是 进一步通过结构生物学方法表征。这些结果将有助于准确估计生殖系 IGHV 6 -1 HA干bnAb的频率,并了解其亲和力成熟途径,这反过来将 有利于设计通用流感疫苗。此外,建立的实验框架, 本研究将适用于表征任何感兴趣的抗体。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nicholas C. Wu其他文献

Stringent and complex sequence constraints of an IGHV1-69 broadly neutralizing antibody to influenza Ha stem
针对流感 Ha 干细胞的 IGHV1-69 广泛中和抗体的严格且复杂的序列限制
  • DOI:
    10.1016/j.celrep.2023.113410
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    8.8
  • 作者:
    Qi Wen Teo;Yiquan Wang;Huibin Lv;Timothy J. C. Tan;R. Lei;Kevin J. Mao;Nicholas C. Wu
  • 通讯作者:
    Nicholas C. Wu
The in vivo ISGylome links ISG15 to metabolic pathways and autophagy upon Listeria monocytogenes infection
体内 ISGylome 将 ISG15 与李斯特菌感染后的代谢途径和自噬联系起来
  • DOI:
    10.1038/s41467-019-13393-x
  • 发表时间:
    2019-11-26
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Yifeng Zhang;Fabien Thery;Nicholas C. Wu;Emma K. Luhmann;Olivier Dussurget;Mariko Foecke;Clara Bredow;Daniel Jiménez-Fernández;Kevin Leandro;Antje Beling;Klaus-Peter Knobeloch;Francis Impens;Pascale Cossart;Lilliana Radoshevich
  • 通讯作者:
    Lilliana Radoshevich
Crystal structure of C05 V110P/A117E mutant bound to H3 influenza hemagglutinin, HA1 subunit
与 H3 流感血凝素、HA1 亚基结合的 C05 V110P/A117E 突变体的晶体结构
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    0
  • 作者:
    A. M. Sevy;Nicholas C. Wu;Iuliia M. Gilchuk;Erica H Parrish;Sebastian Burger;Dina Yousif;Marcus B. M. Nagel;K. Schey;Ian A. Wilson;James E. Crowe;Jens Meiler
  • 通讯作者:
    Jens Meiler
A library-on-library screen reveals the breadth expansion landscape of a broadly neutralizing betacoronavirus antibody
文库上的文库筛选揭示了广泛中和β冠状病毒抗体的广度扩展前景
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Marya Y. Ornelas;Wenhao O. Ouyang;Nicholas C. Wu
  • 通讯作者:
    Nicholas C. Wu
Probing the functional constraints of influenza A virus NEP by deep mutational scanning
通过深度突变扫描探究甲型流感病毒 NEP 的功能限制
  • DOI:
    10.1016/j.celrep.2024.115196
  • 发表时间:
    2025-01-28
  • 期刊:
  • 影响因子:
    6.900
  • 作者:
    Qi Wen Teo;Yiquan Wang;Huibin Lv;Michael S. Oade;Kevin J. Mao;Timothy J.C. Tan;Yang Wei Huan;Joel Rivera-Cardona;Evan K. Shao;Danbi Choi;Chaoyang Wang;Zahra Tavakoli Dargani;Christopher B. Brooke;Aartjan J.W. te Velthuis;Nicholas C. Wu
  • 通讯作者:
    Nicholas C. Wu

Nicholas C. Wu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nicholas C. Wu', 18)}}的其他基金

Biophysical constraints of influenza neuraminidase evolution
流感神经氨酸酶进化的生物物理限制
  • 批准号:
    10654846
  • 财政年份:
    2022
  • 资助金额:
    $ 45.95万
  • 项目类别:
Sequence-function relationship of influenza broadly neutralizing antibodies
流感广泛中和抗体的序列-功能关系
  • 批准号:
    10415666
  • 财政年份:
    2022
  • 资助金额:
    $ 45.95万
  • 项目类别:
Sequence-function relationship of influenza broadly neutralizing antibodies
流感广泛中和抗体的序列-功能关系
  • 批准号:
    10898173
  • 财政年份:
    2022
  • 资助金额:
    $ 45.95万
  • 项目类别:
Biophysical constraints of influenza neuraminidase evolution
流感神经氨酸酶进化的生物物理限制
  • 批准号:
    10522548
  • 财政年份:
    2022
  • 资助金额:
    $ 45.95万
  • 项目类别:
High-throughput identification of antibody features for sequence-based epitope prediction
高通量鉴定抗体特征以进行基于序列的表位预测
  • 批准号:
    10243575
  • 财政年份:
    2021
  • 资助金额:
    $ 45.95万
  • 项目类别:
MECHANISTIC UNDERSTANDING OF INFLUENZA-HOST INTERACTIONS FROM A ZOONOTIC PERSPECTIVE
从人畜共患病的角度理解流感-宿主相互作用的机制
  • 批准号:
    10217310
  • 财政年份:
    2019
  • 资助金额:
    $ 45.95万
  • 项目类别:
MECHANISTIC UNDERSTANDING OF INFLUENZA-HOST INTERACTIONS FROM A ZOONOTIC PERSPECTIVE
从人畜共患病的角度理解流感-宿主相互作用的机制
  • 批准号:
    10242968
  • 财政年份:
    2019
  • 资助金额:
    $ 45.95万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 45.95万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 45.95万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 45.95万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.95万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 45.95万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 45.95万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 45.95万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 45.95万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 45.95万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 45.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了